288 related articles for article (PubMed ID: 11850705)
1. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model.
Ottolini MG; Curtis SR; Mathews A; Ottolini SR; Prince GA
Bone Marrow Transplant; 2002 Jan; 29(2):117-20. PubMed ID: 11850705
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model.
Ottolini MG; Porter DD; Hemming VG; Zimmerman MN; Schwab NM; Prince GA
Bone Marrow Transplant; 1999 Jul; 24(1):41-5. PubMed ID: 10435733
[TBL] [Abstract][Full Text] [Related]
3. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.
Zhao X; Chen FP; Sullender WM
Virology; 2004 Jan; 318(2):608-12. PubMed ID: 14972528
[TBL] [Abstract][Full Text] [Related]
5. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
6. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O
Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
[TBL] [Abstract][Full Text] [Related]
7. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model.
Thomas NJ; Hollenbeak CS; Ceneviva GD; Geskey JM; Young MJ
J Pediatr Hematol Oncol; 2007 Apr; 29(4):227-32. PubMed ID: 17414564
[TBL] [Abstract][Full Text] [Related]
8. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
[TBL] [Abstract][Full Text] [Related]
9. Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy.
Bolger G; Lapeyre N; Dansereau N; Lagacé L; Berry G; Klosowski K; Mewhort T; Liuzzi M
Can J Physiol Pharmacol; 2005 Feb; 83(2):198-213. PubMed ID: 15791294
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting.
Manzoni P; Leonessa M; Farina D; Gomirato G
Pediatr Transplant; 2007 Jun; 11(4):456-7. PubMed ID: 17493231
[No Abstract] [Full Text] [Related]
11. Palivizumab in the prophylaxis of respiratory syncytial virus infection.
Cardenas S; Auais A; Piedimonte G
Expert Rev Anti Infect Ther; 2005 Oct; 3(5):719-26. PubMed ID: 16207163
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
[TBL] [Abstract][Full Text] [Related]
13. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
Weisman LE
Curr Opin Mol Ther; 2009 Apr; 11(2):208-18. PubMed ID: 19330726
[TBL] [Abstract][Full Text] [Related]
14. Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment.
Boukhvalova MS; Yim KC; Kuhn KH; Hemming JP; Prince GA; Porter DD; Blanco JC
J Infect Dis; 2007 Feb; 195(4):511-8. PubMed ID: 17230410
[TBL] [Abstract][Full Text] [Related]
15. Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience.
Tsitsikas DA; Oakervee H; Cavenagh JD; Gribben J; Agrawal SG; Mattes FM
Br J Haematol; 2009 Sep; 146(5):574-6. PubMed ID: 19538531
[No Abstract] [Full Text] [Related]
16. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience.
DeVincenzo JP; Hirsch RL; Fuentes RJ; Top FH
Bone Marrow Transplant; 2000 Jan; 25(2):161-5. PubMed ID: 10673674
[TBL] [Abstract][Full Text] [Related]
17. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus infections: recent prospects for control.
Sidwell RW; Barnard DL
Antiviral Res; 2006 Sep; 71(2-3):379-90. PubMed ID: 16806515
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge.
Fisher RG; Johnson JE; Dillon SB; Parker RA; Graham BS
J Infect Dis; 1999 Sep; 180(3):708-13. PubMed ID: 10438358
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
